Edition:
United States

Alnylam Pharmaceuticals Inc (ALNY.OQ)

ALNY.OQ on NASDAQ Stock Exchange Global Select Market

85.32USD
11:38am EDT
Change (% chg)

$0.80 (+0.95%)
Prev Close
$84.52
Open
$85.52
Day's High
$86.74
Day's Low
$84.15
Volume
129,728
Avg. Vol
399,663
52-wk High
$86.74
52-wk Low
$31.39

ALNY.OQ

Chart for ALNY.OQ

About

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs... (more)

Overall

Beta: 3.00
Market Cap(Mil.): $7,732.54
Shares Outstanding(Mil.): 91.49
Dividend: --
Yield (%): --

Financials

  ALNY.OQ Industry Sector
P/E (TTM): -- 244.33 18.98
EPS (TTM): -4.83 -- --
ROI: -36.21 -7.97 -5.09
ROE: -41.03 -9.96 -4.32

BRIEF-Alnylam CEO, John Maraganore, named BIO chair for 2017-2018 term

* Alnylam CEO, John Maraganore, named BIO chair for 2017-2018 term

Jun 19 2017

BRIEF-Alnylam expands patent portfolio with allowances from U.S. Patent and Trademark Office

* Alnylam significantly expands patent portfolio with new allowances from United States Patent and Trademark Office Source text for Eikon: Further company coverage:

Jun 12 2017

BRIEF-Alnylam Pharmaceuticals expects to end 2017 with over $1 bln in cash, cash equivalents, fixed income marketable securities

* Company updated its cash guidance for year ending december 31, 2017 - sec filing

Jun 06 2017

BRIEF-FDA grants Breakthrough Therapy Designation for Alnylam’S Givosiran for prophylaxis of attacks in patients with acute hepatic porphyria

* FDA grants Breakthrough Therapy Designation for Alnylam’S Givosiran for the prophylaxis of attacks in patients with acute hepatic porphyria

May 31 2017

BRIEF-Alnylam Pharmaceuticals prices public offering of common stock

* Alnylam Pharmaceuticals prices public offering of common stock

May 24 2017

BRIEF-Alnylam Pharmaceuticals reports proposed public offering of common stock

* Alnylam Pharmaceuticals announces proposed public offering of common stock

May 23 2017

BRIEF-Alnylam Pharmaceuticals appoints Manmeet Soni as chief financial officer

* Alnylam Pharmaceuticals Inc - appointment of Manmeet S. Soni as chief financial officer Source text for Eikon: Further company coverage:

May 09 2017

BRIEF-Alnylam Pharmaceuticals files for potential mixed shelf offering

* Files for potential mixed shelf offering; size not disclosed Source text: (bit.ly/2pNQPaG) Further company coverage:

May 05 2017

BRIEF-Alnylam Pharmaceuticals reports Q1 loss per share of $1.25 including items

* Alnylam pharmaceuticals reports first quarter 2017 financial results and highlights recent period activity

May 05 2017

BRIEF-ALNYLAM REPORTS FINAL 24-MONTH RESULTS FROM PHASE 2 OPEN-LABEL EXTENSION STUDY OF PATISIRAN

* ALNYLAM REPORTS FINAL 24-MONTH RESULTS FROM PHASE 2 OPEN-LABEL EXTENSION STUDY OF PATISIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC IN DEVELOPMENT FOR THE TREATMENT OF HEREDITARY ATTR (HATTR) AMYLOIDOSIS

Apr 26 2017

More From Around the Web

Earnings vs. Estimates